Dieser VTCN1 Antikörper ist konjugiert mit PerCP-Cy5.5
Applikation
Flow Cytometry (FACS)
Aufreinigung
The antibody was purified by affinity chromatography and conjugated with PerCP/Cy5.5 under optimal conditions. The solution is free of unconjugated PerCP/Cy5.5 and unconjugated antibody.
B7h4 antikoerper, B7s1 antikoerper, B7x antikoerper, BC032925 antikoerper, B7-H4 antikoerper, B7H4 antikoerper, B7S1 antikoerper, B7X antikoerper, B7h.5 antikoerper, PRO1291 antikoerper, VCTN1 antikoerper, RGD1311204 antikoerper, V set domain containing T cell activation inhibitor 1 L homeolog antikoerper, V-set domain containing T cell activation inhibitor 1 antikoerper, V-set domain containing T-cell activation inhibitor 1 antikoerper, V set domain containing T cell activation inhibitor 1 antikoerper, vtcn1.L antikoerper, VTCN1 antikoerper, vtcn1 antikoerper, Vtcn1 antikoerper
Hintergrund
B7-H4, also known as VTCN1, is a type I transmembrane protein and member of the B7 family. Its extracellular region consists of one IgV-like and one IgC-like domain. B7-H4 expression has been reported on activated T cells, B cells, monocytes, and dendritic cells. On T cells, B7-H4 inhibits proliferation, cytokine secretion, and cytotoxicity. B7-H4 is also expressed by different carcinomas including renal, gastric, breast, ovarian and melanoma. Its expression is associated with a poor prognosis.